VialBPC-157 30 mg cartridge
Tissue repair
Investigated for gut barrier integrity and tissue repair.
- Ships from Canada in 1–2 business days
- Free shipping over $120
Place your order, then send the e-Transfer. We pack it as soon as it arrives.
For research use only. Not for human consumption.
Complete your setup
A cartridge goes in the reusable pen.
- Reusable Metal Pen
$49.00 · Holds the cartridge · reusable
- Alcohol Wipes
Free · To wipe the pen's rubber seal
Compare. Side by side, from the research.
About BPC-157
BPC-157 is a synthetic sequence derived from a protein found in gastric juice. Research examines its role in gut barrier integrity, connective-tissue repair, and the signaling that coordinates healing.
How it works
- Angiogenic Signaling
- Studied for its relationship with VEGF-associated pathways involved in forming the microvasculature that supports repair.
- Gut Barrier
- Explored for a role in maintaining the integrity of the intestinal lining under inflammatory stress.
What you need
- Reusable Metal Pen
- Alcohol Wipes
- A protocol guide comes with every order
Shipping & payment
- Packed and dispatched within 1–2 business days
- Delivered across Canada in 2–5 business days, tracked
- Temperature-controlled packaging where the product needs it
- Free shipping on orders over $120
- Prices in CAD · pay by Interac e-Transfer
- Format
- Single cartridge for the reusable CoreX pen
- Strength
- 30 mg per cartridge
- Storage
- Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
- Route in research
- Subcutaneous
- SKU
- BC30SC
- Purity
- High-performance liquid chromatography (HPLC), by an independent laboratory
- Identity
- Mass spectrometry, on the same batch
- How often
- Every batch
- COA
- The certificate of analysis is matched to the lot code printed on your vial
- Evidence
- Early clinical
Check your lot
Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.
Early clinicalMost BPC-157 research consists of animal and preclinical work, with a small number of limited human reports, such as a study of intra-articular injection for knee pain, and no large controlled trials identified.
What research examines
- Musculoskeletal soft tissue healing
- Wound healing
- Gastroprotection and gut barrier integrity
- Angiogenic and VEGF-associated signaling in repair
- Knee pain in a small human report
- Applications in orthopaedic sports medicine
Reported in studies
- Human safety data are limited
- Adverse events are not systematically summarized in the cited studies
- Published reviews have raised questions about potential risks alongside proposed regenerative benefits
- Long-term safety has not been established in controlled human trials
Published research protocols
500 mcg, twice daily, am + pm
Research protocols have used 250–1,000 mcg per administration, twice daily, in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Measure with the calculatorCoreX AI
Ask about BPC-157
Plain answers, from the basics to the studies.
Research information, not medical advice.
Often researched with BPC-157
Researched for recovery & repair.
Vial
Vial
Vial
FAQ
Questions, answered
BPC-157 is a synthetic peptide sequence derived from a protein found in gastric juice, often described in the literature as a gastric pentadecapeptide or body protection compound. Research examines its role in gut barrier integrity, connective-tissue repair, and the signaling that coordinates healing. It is supplied by CoreX for laboratory research use only, and most published work on it comes from animal and preclinical studies.
Research investigates BPC-157 for its influence on angiogenic signaling and growth-factor receptor expression at sites of tissue stress. It has been studied for its relationship with VEGF-associated pathways involved in forming the microvasculature that supports repair. Separate lines of research have explored a role in maintaining the integrity of the intestinal lining under inflammatory stress. These proposed mechanisms come largely from preclinical models and are not fully characterized in humans.
Published reviews describe research on BPC-157 in musculoskeletal soft tissue healing, including tendon, ligament and muscle models, as well as wound healing and gastroprotection. Recent systematic and narrative reviews have examined its emerging use in orthopaedic sports medicine. A small human report described intra-articular injection for several types of knee pain. Overall, the evidence base is dominated by animal studies, and large controlled human trials are lacking.
Human safety data for BPC-157 are limited. Adverse events are not systematically summarized in the cited studies, and no large controlled trials have established a safety profile. A 2025 narrative review framed the topic as regeneration or risk, reflecting uncertainty about potential harms alongside proposed benefits. Reviews aimed at orthopaedic and sports medicine clinicians have also highlighted challenges and open questions surrounding injectable peptides such as BPC-157.
Research protocols have used 250 to 1,000 mcg per administration, twice daily, in 8-week blocks followed by 4 weeks off, with subcutaneous administration described. These figures reflect what protocols have reported and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. Because controlled human dose-finding studies are lacking, these ranges should be viewed in the context of a largely preclinical evidence base.
You may also like
Vial · Pen
Vial · Pen
Vial
Vial
